DrugPatentWatch Database Preview
ALNYLAM Company Profile
» See Plans and Pricing
What is the competitive landscape for ALNYLAM, and when can generic versions of ALNYLAM drugs launch?
ALNYLAM has three approved drugs.
There are forty US patents protecting ALNYLAM drugs.
There are seven hundred and eleven patent family members on ALNYLAM drugs in forty-nine countries and twenty-six supplementary protection certificates in fifteen countries.
Summary for ALNYLAM
| International Patents: | 711 |
| US Patents: | 40 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
Drugs and US Patents for ALNYLAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | 9,828,606 | Start Trial | Y | Y | Start Trial | ||
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 9,943,538 | Start Trial | Y | Start Trial | |||
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 9,193,753 | Start Trial | Start Trial | ||||
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 8,895,718 | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ALNYLAM Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 218881 | Start Trial |
| Germany | 10080167 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2015051318 | Start Trial |
| Canada | 2522349 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ALNYLAM Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1407044 | 132019000000031 | Italy | Start Trial | PRODUCT NAME: PATISIRAN(ONPATTRO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1320, 20180829 |
| 2937418 | LUC00098 | Luxembourg | Start Trial | PRODUCT NAME: PATISIRAN ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (ONPATTRO ); AUTHORISATION NUMBER AND DATE: EU/1/18/1320 20180829 |
| 2937418 | C20190005 00300 | Estonia | Start Trial | PRODUCT NAME: PATISIRAAN;REG NO/DATE: EU/1/18/1320 29.08.2018 |
| 2937418 | 300965 | Netherlands | Start Trial | PRODUCT NAME: PATISIRAN; REGISTRATION NO/DATE: EU/1/18/1320 20180829 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
